CardioGenics Holdings Inc banner

CardioGenics Holdings Inc
OTC:CGNH

Watchlist Manager
CardioGenics Holdings Inc Logo
CardioGenics Holdings Inc
OTC:CGNH
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: $9.6k

P/S

0
Current
No historical data
Comparison unavailable

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
0
=
Market Cap
$0
/
Revenue
$0

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
0
=
Market Cap
$0
/
Revenue
$0

Valuation Scenarios

CardioGenics Holdings Inc is trading above its industry average

If P/S returns to its Industry Average (6.7), the stock would be worth $0 (100% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-100%
Maximum Upside
No Upside Scenarios
Average Downside
100%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 0 $0
0%
Industry Average 6.7 $0
-100%
Country Average 2.4 $0
-100%

Forward P/S
Today’s price vs future revenue

Not enough data available to calculate forward P/S

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
US
CardioGenics Holdings Inc
OTC:CGNH
9.6k USD 0 -0
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7
US
Abbvie Inc
NYSE:ABBV
360.5B USD 5.9 86.1
US
Amgen Inc
NASDAQ:AMGN
182.2B USD 5 23.6
US
Gilead Sciences Inc
NASDAQ:GILD
159.9B USD 5.4 18.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.5B USD 9 27.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.5B USD 5.1 16.1
NL
argenx SE
XBRU:ARGX
40.6B EUR 11.4 36.7
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8
AU
CSL Ltd
ASX:CSL
60.6B AUD 2.7 29.7
P/S Multiple
Revenue Growth P/S to Growth
US
CardioGenics Holdings Inc
OTC:CGNH
Average P/S: 3 369 302.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
5%
1.1
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9
11%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
10%
0.5
NL
argenx SE
XBRU:ARGX
11.4
28%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
AU
CSL Ltd
ASX:CSL
2.7
4%
0.7
P/E Multiple
Earnings Growth PEG
US
CardioGenics Holdings Inc
OTC:CGNH
Average P/E: 34
Negative Multiple: -0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.1
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23.6
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
14%
1.2
NL
argenx SE
XBRU:ARGX
36.7
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.7
9%
3.3

Market Distribution

Not Available
No Country distribution data available for this multiple

CardioGenics Holdings Inc
Glance View

Market Cap
9.6k USD
Industry
Biotechnology

CardioGenics Holdings, Inc. is a biotechnology company, which engages in the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2004-06-09. The firm has developed the QL Care Analyzer, a point-of-care immuno-analyzer, which is capable of running approximately 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its technology, the Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improves instrument sensitivity to light.

CGNH Intrinsic Value
Not Available
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett